Evaluation technologies
The field needs new evaluation tools
New and enhanced evaluation technologies are needed to inform decision-making around malaria vaccine candidates, including decisions around the initiation of human trials. The most significant challenge that malaria vaccine scientists face is a lack of understanding of the specific immune responses associated with protection against the parasitic disease. Successful development of evaluation tools, including assays and human challenge models, that correlate to the immune response in people is therefore a critical need.
MVI’s activities include support for the development and refinement of evaluation tools, such as immunological assays and clinical and preclinical malaria challenge models. This range of activities should provide robust data to inform decision-making around the development of vaccine candidates and to reduce development investment risk.
Our activities include:
- Identifying and engaging partners to drive the development and qualification of tools for assessing vaccine candidates.
- Upgrading the capabilities of existing reference and service centers for immunological assays.
- Supporting toxicology testing at a centralized toxicology testing service center.
- Supporting the development of standardized and high-quality control standards and reagents for the conduct of immunoassays.
